AR031613A1 - Derivados de piridina, un medicamento, una composicion farmaceutica, un inhibidor de la quinasa betaikappab, un medicamento anti-inflamatorio, un inmunosupresor, un medicamento para la isquemia, un medicamento anti-tumoral y el uso de dichos derivados para la preparacion de un medicamento - Google Patents

Derivados de piridina, un medicamento, una composicion farmaceutica, un inhibidor de la quinasa betaikappab, un medicamento anti-inflamatorio, un inmunosupresor, un medicamento para la isquemia, un medicamento anti-tumoral y el uso de dichos derivados para la preparacion de un medicamento

Info

Publication number
AR031613A1
AR031613A1 ARP010104446A ARP010104446A AR031613A1 AR 031613 A1 AR031613 A1 AR 031613A1 AR P010104446 A ARP010104446 A AR P010104446A AR P010104446 A ARP010104446 A AR P010104446A AR 031613 A1 AR031613 A1 AR 031613A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
hydrogen
alkanoyl
aminocarbonyl
Prior art date
Application number
ARP010104446A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR031613A1 publication Critical patent/AR031613A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/08—Preparation by ring-closure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/08—Preparation by ring-closure
    • C07D213/09—Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles
    • C07D213/10—Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from acetaldehyde or cyclic polymers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems

Abstract

Derivados de piridina, que comprenden un derivado de formula (1), en la que: R1 representa un resto de formula (2), (3) o (4), en la que R11 es hidrogeno, alquilo C1-6, halogeno, hidroxi, alcoxi C1-12, nitro, amino, alquil C1-6-sulfonilamino, alcoxi C1-6-carbonilo, alquil C1-6-amino, di(alquil C1-6)amino, alcanoil C1-6-amino, fenilalquil C1-6-amino, fenilsulfonilamino o -O-(CH2)n-R111, en la que n representa un numero entero seleccionado entre 0 y 6, y R111 es alquenilo C2-6, benzoilo, difenilmetilo, di(alquil C1-6)amino, alcanoilo C1-6alcoxi C1-6carbonilo, o un anillo saturado o insaturado de 3-10 miembros que presenta de 0-3 heteroátomos seleccionados del grupo constituido por S, O y N como heteroátomos y está opcionalmente sustituido por alquilo C1-6, mono o dihalogeno, alquilo C1-6 sustituido con halogeno, nitro, ciano, alcoxi C1-6-carbonilo, fenilo, hidroxi, amino, alquil C1-6-amino, di(alquilC1-6)amino, alcanoil C1-6-amino, alcoxi C1-6 o carbamoilo; R2 representa hidrogeno o halogeno; R3 representa hidrogeno o 1,2,3,4-tetrahidropiridina, CR31R32R33, en la que R31 es hidrogeno o alquilo C1-6, R32 es hidrogeno, alfa-aminobencilo, alquilo C1-6 opcionalmente sustituido por uno o dos sustituyentes seleccionados del grupo constituido por hidroxi, amino, fenilo sustituido con amino, fenilo, fenilo sustituido con halogeno y fenilo sustituido con alcoxi C1-6, o un anillo saturado de 5-8 miembros que presenta de 0-3 heteroátomos seleccionados entre el grupo constituido por S, O y N como heteroátomos y opcionalmente sustituidos por alquilo C1-6, y R33 es hidrogeno, amino, alcoxi C1-6-carbonilamino, alquenil C2-6-oxicarbonilamino, piperidinalquil C1-6-carbonilamino, piperidinialquil C1-6-carbonilamino, o R32 y R33 pueden formar, junto con el átomo de carbono adyacente un anillo saturado de 5-8 miembros que presente de 0-3 heteroátomos seleccionados del grupo constituido por N, O y S como heteroátomos, cuyo anillo está opcionalmente sustituido con fenilalquilo C1-6, fenilalquilo C1-6 sustituido con alcoxi C1-6, alquilo C1-6, amino, ciano, hidroxi, carbamoilo, carboxi, alquil C1-6-amino, alcoxi C1-6-carbonilo, di(alquilo C1-6)amino, bencilamino, alquil C1-6-sulfonilo, piperidinalquil C1-6-carbonilo u opcionalmente fusionado por benceno; o -NR34R35, en la que R34 es hidrogeno o alquilo C1-6, y R35 es hidrogeno, un anillo saturado de 5-8 miembros que presenta de 0-3 heteroátomos seleccionados del grupo constituido por N, O, y S como heteroátomos, o -(CH2)m-NR351R352 (m representa cualquier numero entero de 1 a 6), en la que R351representa hidrogeno o alquilo C1-6, y R352 representa hidrogeno, alquilo C1-6, alcanoilo C1-6, fenilo sustituido con alquilo C1-6, benzoilo, alcanoilo C1-6, fenilaminocarbonilo, fenilsulfonilo, o R34 y R35 pueden formar, junto con el átomo de N adyacente, un anillo heterocíclico saturado de 5-8 miembros, y el mencionado anillo puede contener opcionalmente NH, átomos de S u O distintos del átomo de N adyacente y opcionalmente sustituido por carbamoilo, amino o alquilo C1-6; R4 representa hidroxicarbonilo, alcanoilo C1-6, carbamoilo, ciano, nitro, carbonilo, alcoxi C1-6-carbonilo, alquil C1-6-carbamoilo, alquil C1-6-amino, heteroaril(hidroxi)metilo de 5-10 miembros, heteroarilalquilo C1-6 de 5-10 miembros o metilo sustituido por hidroxi y un anillo cíclico saturado de 5-7 miembros, alquilo C1-6 opcionalmente sustituido por un sustituyente seleccionado del grupo constituido por hidroxi, alcoxi C1-6, alquilo C1-6-sulfonilamino, alquil C1-6-carbonilamino, arilo C5-10, aril C5-10-sulfonilo, aril C5-10-sulfanilo, aril C5-10-oxi, imidazolilo o pirrolidinoxi sustituido con dioxo, -(CH2)pNHCOR41, -(CH2)pNCH(=S)R41, en las que p representa cualquier numero entero de 1 a 6 y R41 representa alcoxi C1-6, amino, fenilamino, alquilo C1-6, alquil C1-6-amino, di(alquil C1-6)amino, cicloalquil C3-10-amino; R3 y R4 pueden formar junto con los átomos de carbono en el anillo de piridina, monocicloalquilo o bicicloalquilo de 4-10 miembros opcionalmente interrumpidos por NH y opcionalmente sustituidos por bencilo, =NH o =O; R5 representa NR51R52, en la que R51 es hidrogeno o alquilo C1-6; R52 es hidrogeno, alquilo C1-6, fenilo, bencilo, alcanoilo o NR51R52 puede formar un anillo saturado de 5-6 miembros que contienen opcionalmente NH u O como otro heteroátomo distinto al átomo de N adyacente; o R4 y R5 pueden formar, -R40-CO-NH-, -R40-SO2-NH-, -R40-C(=S)-NH-, -R40-CH2-NH-, en las que el mencionado R40 representa -CHR401-O-, -CH2-NR401, -CO-NR401, CH2CHR401, -CH=CR401 (en las cuales R401 es alcanoilo C1-6, alquilo C1-6, fenilo, alquil C1-6-sulfonilo, cicloalquil C3-8-aminocarbonilo, hidrogeno, halogeno, nitro, amino, ciano, benzoilamino, fenilsulfonilo, carbamoilo, hidroxicarbonilo, alcoxi C1-6-carbonilo, alquil C1-12-aminicarbonilo, alquil C1-6-aminocarbonilo sustituido con halogeno, alcanoil C1-6-amino, di(alquil C1-6)aminocarbonilo, di(alquil C1-6)aminoalquil C1-6-aminocarbonilo, hidroindenilaminocarbonilo, difenilmetilaminocarbonilo, pirrolidincarbonilo, alcoxi C1-6-alquil C1-6-aminocarbonilo, morfolincarbonilo, piperazinacarbonilo, fenilalquil C1-6-aminocarbonilo, hidroxicarbonilalquil C1-6-aminocarbonilo, cicloalquil C3-8-aminocarbonilo, cicloalquil C3-8-alquil C1-6-aminocarbonilo, hidroxialquil C1-6-aminocarbonilo, carboxietilaminocarbonilo, alquil C1-6-sulfonilaminocarbonilo), -CR41=N-NH- (donde R41 es hidrogeno, amino o alcanoil C1-6-amino), -CR42=N-C=N- (donde R42 es hidrogeno o amino); o una sal del mismo; un medicamento, una composicion farmacéutica, un inhibidor de la quinasa betaIkappaB, un medicamento anti-inflamatorio, un inmunosupresor, un medicamento para la isquemia, un medicamento anti-tumoral y el uso de dichos derivados para la preparacion de un medicamento.
ARP010104446A 2000-09-22 2001-09-20 Derivados de piridina, un medicamento, una composicion farmaceutica, un inhibidor de la quinasa betaikappab, un medicamento anti-inflamatorio, un inmunosupresor, un medicamento para la isquemia, un medicamento anti-tumoral y el uso de dichos derivados para la preparacion de un medicamento AR031613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000289173A JP4272338B2 (ja) 2000-09-22 2000-09-22 ピリジン誘導体

Publications (1)

Publication Number Publication Date
AR031613A1 true AR031613A1 (es) 2003-09-24

Family

ID=18772618

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104446A AR031613A1 (es) 2000-09-22 2001-09-20 Derivados de piridina, un medicamento, una composicion farmaceutica, un inhibidor de la quinasa betaikappab, un medicamento anti-inflamatorio, un inmunosupresor, un medicamento para la isquemia, un medicamento anti-tumoral y el uso de dichos derivados para la preparacion de un medicamento

Country Status (31)

Country Link
US (4) US6562811B1 (es)
EP (1) EP1326856B1 (es)
JP (1) JP4272338B2 (es)
KR (1) KR20030030030A (es)
CN (1) CN1476442A (es)
AR (1) AR031613A1 (es)
AT (1) ATE381556T1 (es)
AU (3) AU2001289873A1 (es)
BG (1) BG107632A (es)
BR (1) BR0114073A (es)
CA (1) CA2422923A1 (es)
DE (1) DE60132001T2 (es)
EC (1) ECSP034524A (es)
EE (1) EE200300113A (es)
ES (1) ES2298260T3 (es)
GT (1) GT200100189A (es)
HR (1) HRP20030306A2 (es)
HU (1) HUP0303124A2 (es)
IL (1) IL154550A0 (es)
MA (1) MA25836A1 (es)
MX (1) MXPA03002491A (es)
NO (1) NO20031307D0 (es)
NZ (1) NZ524811A (es)
PE (1) PE20020508A1 (es)
PL (1) PL361811A1 (es)
RU (1) RU2003111754A (es)
SK (1) SK3452003A3 (es)
SV (1) SV2002000637A (es)
UY (1) UY26943A1 (es)
WO (3) WO2002024679A1 (es)
ZA (1) ZA200302226B (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) * 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
WO2005016455A2 (en) 2003-08-14 2005-02-24 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
ES2305125T3 (es) 2000-10-26 2008-11-01 Amgen Inc. Agentes anti-inflamatorios.
JP2002193938A (ja) * 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) * 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
ES2345096T3 (es) * 2002-02-13 2010-09-15 F. Hoffmann-La Roche Ag Nuevos derivados de piridina y pirimidina.
JP2003277383A (ja) * 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
JP4690889B2 (ja) 2002-10-24 2011-06-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング メチレン尿素誘導体
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
AU2004278382B2 (en) * 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0323137D0 (en) * 2003-10-03 2003-11-05 Chang Lisa C W 2,4,6- Trisubstituted pyrimidines and their different uses
UA83101C2 (en) * 2003-12-15 2008-06-10 Алмирал Аг 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
US20050154022A1 (en) * 2004-01-14 2005-07-14 H. Lundbeck A/S 4-aryl piperidines
EP1736472A4 (en) * 2004-04-15 2007-10-31 Astellas Pharma Inc 2-aminopyridine derivative
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
GB0415364D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
AU2005310238A1 (en) * 2004-10-29 2006-06-08 Merck Sharp & Dohme Corp. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
KR101152605B1 (ko) 2004-12-21 2012-06-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법 및 이를 포함하는약제조성물
FR2888579A1 (fr) * 2005-07-13 2007-01-19 Aventis Pharma Sa Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
ATE502936T1 (de) * 2005-04-11 2011-04-15 Almirall Sa 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
JP2008540438A (ja) * 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なピリジン
WO2007005534A2 (en) 2005-06-30 2007-01-11 Smithkline Beecham Corporation Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102005036655A1 (de) * 2005-08-04 2007-02-08 Bayer Healthcare Ag Behandlung von Tumoren mit IKK-ß Inhibitoren
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
WO2007106884A2 (en) 2006-03-15 2007-09-20 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2007125331A2 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (aeaa) compounds and their use
ZA200902382B (en) * 2006-10-19 2010-08-25 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
CN101679371A (zh) * 2006-12-04 2010-03-24 艾美罗股份公司 作为腺苷受体拮抗剂的取代的嘧啶
AU2007334321B2 (en) * 2006-12-18 2012-03-08 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
JP2010522214A (ja) * 2007-03-21 2010-07-01 アルミラル， エセ．アー． アデノシンレセプターアンタゴニストとしての置換ピリミジン
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
ES2442847T3 (es) 2007-04-18 2014-02-13 Amgen, Inc Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa
EP2155746A2 (en) 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones that inhibit prolyl hydroxylase activity
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2227460B1 (en) * 2007-10-24 2012-06-20 Cancer Research Technology Limited Therapeutic oxy-phenyl-aryl compounds and their use
CA2707494C (en) * 2007-12-07 2018-04-24 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
KR20100101130A (ko) 2007-12-07 2010-09-16 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US8343966B2 (en) * 2008-01-11 2013-01-01 Novartis Ag Organic compounds
NZ602030A (en) 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
RU2499592C2 (ru) 2008-04-21 2013-11-27 Отономи, Инк. Фармацевтическая композиция для лечения ушных заболеваний
WO2010007756A1 (ja) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
JP5511693B2 (ja) 2009-02-03 2014-06-04 クミアイ化学工業株式会社 縮合環化した２−ピリドン誘導体及び除草剤
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
JP2012162460A (ja) * 2009-05-27 2012-08-30 Nippon Soda Co Ltd 含窒素ヘテロアリール誘導体および農園芸用殺菌剤
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
EP2789615B1 (en) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
US20120053235A1 (en) * 2010-08-30 2012-03-01 Hong Kong Baptist University Dihydromyricetin as an IKK-beta inhibitor used for treatment of arthritis, cancer and autoimmune conditions, and other diseases or disorders
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
PT2797416T (pt) 2011-12-28 2017-10-23 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
AU2013337086B2 (en) * 2012-10-08 2017-06-15 Cancer Research Technology Limited 2-aminopyridine compounds
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
JP6473457B2 (ja) 2014-01-17 2019-02-20 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
DK3102208T3 (da) 2014-02-07 2021-03-08 Global Blood Therapeutics Inc Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
CN104860870A (zh) * 2014-02-26 2015-08-26 欧美嘉股份有限公司 具有不同取代基的哌啶的制备方法
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
AU2016250976B2 (en) 2015-04-21 2020-02-27 Jiangsu Hengrui Medicine Co., Ltd. Imidazo isoindole derivative, preparation method therefor and medical use thereof
US10758522B2 (en) 2015-06-01 2020-09-01 The Scripps Research Institute Small molecule analogs of the nemo binding peptide
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
CN112625028A (zh) 2015-06-19 2021-04-09 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
EA036446B1 (ru) 2016-06-14 2020-11-11 Новартис Аг Соединения и композиции для подавления активности shp2
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN107417605A (zh) * 2017-08-02 2017-12-01 江苏艾立康药业股份有限公司 作用于脯氨酰羟化酶的吡啶衍生化合物
RU2669348C1 (ru) * 2017-11-15 2018-10-10 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ ингибирования нуклеарного фактора каппа В с использованием 2-этил-6-метил-3-гидроксипиридиния L-2,6-диаминогексаноата в культуре клеток
WO2019173653A1 (en) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003908A (en) * 1976-03-11 1977-01-18 E. R. Squibb & Sons, Inc. Derivatives of imidazo(4,5-b)pyridines
PE20010635A1 (es) * 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas

Also Published As

Publication number Publication date
PE20020508A1 (es) 2002-07-13
JP2002114777A (ja) 2002-04-16
ECSP034524A (es) 2003-04-25
EP1326856A1 (en) 2003-07-16
AU2001289875A1 (en) 2002-04-02
US6562811B1 (en) 2003-05-13
SK3452003A3 (en) 2004-01-08
JP4272338B2 (ja) 2009-06-03
BR0114073A (pt) 2003-06-17
IL154550A0 (en) 2003-09-17
NZ524811A (en) 2004-10-29
CA2422923A1 (en) 2002-03-28
WO2002024693A1 (en) 2002-03-28
HRP20030306A2 (en) 2005-04-30
CN1476442A (zh) 2004-02-18
ZA200302226B (en) 2004-03-23
WO2002024651A1 (en) 2002-03-28
US7232909B2 (en) 2007-06-19
US20060100246A1 (en) 2006-05-11
RU2003111754A (ru) 2004-10-27
DE60132001D1 (de) 2008-01-31
US7435743B2 (en) 2008-10-14
NO20031307L (no) 2003-03-21
PL361811A1 (en) 2004-10-04
EE200300113A (et) 2005-02-15
ES2298260T3 (es) 2008-05-16
SV2002000637A (es) 2002-12-02
US20060205676A1 (en) 2006-09-14
DE60132001T2 (de) 2008-12-04
WO2002024679A1 (en) 2002-03-28
NO20031307D0 (no) 2003-03-21
GT200100189A (es) 2002-05-16
BG107632A (bg) 2003-11-28
ATE381556T1 (de) 2008-01-15
MXPA03002491A (es) 2004-12-06
EP1326856B1 (en) 2007-12-19
AU2001289873A1 (en) 2002-04-02
AU2001291852A1 (en) 2002-04-02
MA25836A1 (fr) 2003-07-01
KR20030030030A (ko) 2003-04-16
UY26943A1 (es) 2002-04-26
HUP0303124A2 (hu) 2003-12-29
US6984649B1 (en) 2006-01-10

Similar Documents

Publication Publication Date Title
AR031613A1 (es) Derivados de piridina, un medicamento, una composicion farmaceutica, un inhibidor de la quinasa betaikappab, un medicamento anti-inflamatorio, un inmunosupresor, un medicamento para la isquemia, un medicamento anti-tumoral y el uso de dichos derivados para la preparacion de un medicamento
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
AR040408A1 (es) Derivados de benzotiadiazepina, procesos para su preparacion y composiciones farmaceuticas que los contienen
RU2424240C2 (ru) Антибактериальные производные пиперидина
TW200700387A (en) 1-benzylindole-2-carboxamide derivatives
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
AR030553A1 (es) Uso de derivados de tiazolilo 2,4-disustituidos para la fabricacion de un medicamento para la prevencion o el tratamiento de enfermedades mediadas a traves de citoquinas, derivados de tiazolilo 2,4-disustituidos, composiciones farmaceuticas que los comprenden, procesos para preparar dichos derivados
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
ES2328820T3 (es) Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
ES2333802T3 (es) Inhibidores no nucleicos de transcriptasa inversa.
AR033836A1 (es) Compuesto 2-anilino-(imidazol-5-il)-pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento que produce un efecto inhibitorio del ciclo celular y un proceso para su preparacion
AR050208A1 (es) Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
AR063643A1 (es) Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR038888A1 (es) Amidas heterociclicas
AR017177A1 (es) Compuesto derivados de 9-amino-3-ceto eritromicina, composiciones farmaceuticas, uso para la preparacion de un medicamento y procedimientos de preparacion.
AR064208A1 (es) Derivados de piridin-3-il-quinazolinas como inhibidores de b-raf. procesos de obtencion y composiciones farmaceuticas.
AR063690A1 (es) Derivados de 1h-pirrol-2-il-carbonilo sustituidos, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento util en el tratamiento de infecciones bacterianas.
AR047702A1 (es) Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular
AR042690A1 (es) Derivados de pirrolil-tiazol como agonistas inversos de receptores cb1; preparacion de los mismos y composiciones farmaceuticas que los contienen
AR076899A1 (es) Derivados heterociclicos de la urea, composiciones farmaceuticas y su uso en el tratamiento de infecciones bacterianas
AR038887A1 (es) Amidas heterociclicas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal